Drs. Pegram and Garrido-Castro analyze the PFS and OS data from both Trop−2 ADC trials. Learn why differences in trial populations make direct comparison misleading, and what the OS benefit in TROPION-Breast02 means when deciding on a preferred first-line agent in mTNBC.
Endpoints and Heterogeneity: A Critical Look at PFS and OS in TROPION−Breast02 and ASCENT−03
You may also like
Recommended Videos
